Evonik Evonik

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"Tome Biosciences","sponsor":"Andreessen Horowitz","pharmaFlowCategory":"D","amount":"$118.0 million","upfrontCash":"Undisclosed","newsHeadline":"Tome Biosciences Launches with Over $200 Million in Funding to Advance Programmable Genomic Integration Platform","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Discovery","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"December 2023","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Discovery"},{"orgOrder":0,"company":"Tome Biosciences","sponsor":"Genevant Sciences","pharmaFlowCategory":"D","amount":"$114.3 million","upfrontCash":"Undisclosed","newsHeadline":"Genevant Sciences to Collaborate with Tome Biosciences to Develop Gene Editing Therapeutic for Rare Liver Disorder","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Discovery Platform","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"January 2024","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Discovery Platform"}]

    Find Clinical Drug Pipeline Developments & Deals by Tome Biosciences

    Menu

    Tome Biosciences

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              Tome Biosciences

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Genevant Sciences to Collaborate with Tome Biosciences to Develop Gene Editing Therapeutic for Rare Liver Disorder

              Details:

              Under the collaboration, Genevant will combine its proprietary LNP technology with Tome’s programmable genomic integration (PGI) technology to develop an in vivo gene editing treatment for an undisclosed rare monogenic liver disorder.

              Lead Product(s): Undisclosed

              Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: Undisclosed

              Highest Development Status: Discovery Platform Product Type: Cell and Gene therapy

              Recipient: Genevant Sciences

              Deal Size: $114.3 million Upfront Cash: Undisclosed

              Deal Type: Collaboration January 16, 2024

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Tome Biosciences

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Tome Biosciences Launches with Over $200 Million in Funding to Advance Programmable Genomic Integration Platform

              Details:

              The Company intends to use the net proceeds to develop integrative gene therapies for monogenic liver diseases and cell therapies for autoimmune diseases.

              Lead Product(s): Undisclosed

              Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: Undisclosed

              Highest Development Status: Discovery Product Type: Cell and Gene therapy

              Partner/Sponsor/Collaborator: Andreessen Horowitz

              Deal Size: $118.0 million Upfront Cash: Undisclosed

              Deal Type: Series B Financing December 12, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              Minakem offers CDMO services for API & HPAPI, generics, regulatory expertise, track record performance & FDA & GMP certifications.
              Temad- We think of world-class quality.
              Post Enquiry
              POST ENQUIRY